Genmab Calls March 19 AGM to Approve 2025 Results and Capital Reduction

Genmab ( (GMAB) ) has shared an announcement.

Genmab A/S has convened its 2026 Annual General Meeting for March 19, 2026, at the Copenhagen Marriott Hotel, where shareholders will review 2025 performance, vote on the audited annual report and compensation report, and consider board and auditor elections. The board proposes carrying forward the 2025 profit of USD 963 million to retained earnings, maintaining 2026 board and committee fees at 2025 levels, and re-electing six directors, preserving a diverse and largely independent board while also seeking approval to reduce share capital via cancellation of treasury shares, which would modestly enhance capital structure efficiency and per-share metrics.

Shareholders will also vote on reappointing Deloitte as auditor, including a limited assurance mandate on sustainability statements, underscoring Genmab’s focus on governance and ESG disclosure. The meeting agenda, including authorization of the chair to implement resolutions, reflects a continuation of the company’s current strategic and governance framework, with no major shifts in capital allocation but a clear emphasis on stability, board continuity and incremental capital optimization through the proposed share capital reduction.

The most recent analyst rating on (GMAB) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab A/S is an international biotechnology company focused on developing innovative antibody-based medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, it has built a diversified portfolio spanning bispecific antibodies, antibody–drug conjugates and other next-generation modalities, with eight approved antibody treatments and a strong late-stage clinical pipeline worldwide.

The company operates across North America, Europe and Asia Pacific, leveraging its scientific platforms to deliver transformative therapies and expand its global presence. Its business model combines wholly owned programs with partnered products, positioning Genmab as a key player in the oncology and antibody-therapeutics market.

Average Trading Volume: 1,609,924

Technical Sentiment Signal: Buy

Current Market Cap: $18.6B

For detailed information about GMAB stock, go to TipRanks’ Stock Analysis page.